Automatic Website Traffic RSS

'One-two punch' of epigenetic cancer drugs could knock out colorectal cancer cells

The researchers used a type of decitabine commercialized as Dacogen by Otsuka; tazemetostat is commercialized by Ipsen as Tazverik. Neither company was involved in the study. While agents in both ... read more

Venclexta for AML

Venclexta is used with either azacitidine (Onureg, Vidaza), decitabine (Dacogen), or cytarabine. These are chemotherapy drugs. You should swallow Venclexta tablets whole with a drink of water. read more

Bio-Path (BPTH) Rises on Upbeat Updates From Blood Cancer Study

Bio-Path (BPTH) gains 30% on encouraging developmental updates from the early-stage study of its investigational candidate, BP1002, to treat acute myeloid leukemia patients. read more

Celgene Profit Swells (Update)

Vidaza sales are accelerating after Celgene relaunched the drug following the completion of the Pharmion acquisition and the release of negative survival data for Dacogen, a competing drug ... read more

Improving Cancer Care: The Role of Oral Hypomethylating Agents and Education

Investigators say oral formulations of hypomethylating agents could be a significant advancement for people with myelodysplastic syndromes and acute myeloid leukemia. read more

A new path to the cancer epigenome

The approval of azacitidine (Vidaza) in 2004 and decitabine (Dacogen) in 2006 for the treatment of myelodysplastic syndrome demonstrated that DNA hypomethylating agents can provide patient benefit ... read more

Dr. Redkar Unveils the Role of Targeted and Histology-Agnostic Therapies in Cancer Treatment

In an exclusive interview with ONCOLife, Dr. Sanjeev Redkar, explains the importance of therapies like vebreltinib and uproleselan in cancer treatment, emphasizing the push towards histology-agnostic ... read more